Baker Botts Represents EQT Corporation in $1.18 Billion Sale of Jupiter Gas Gathering System

Thursday, May 1, 2014
EQT Corporation (NYSE: EQT) today announced that EQT Midstream Partners, LP (NYSE: EQM) (Partnership) has agreed to acquire EQT’s Jupiter natural gas gathering system (Jupiter) for $1.18 billion. EQT will receive $1.12 billion of cash and $59 million of common and general partner units. The Jupiter system gathers EQT’s Marcellus production in portions of Greene and Washington Counties, Pennsylvania, and consists of approximately 35 miles of natural gas gathering pipeline and approximately 21,300 horsepower of compression. Jupiter has a total of 970 MMcf per day of pipeline capacity and six interconnects with the Partnership’s transmission and storage systems.

More >>

Tags:  Baker Botts L.L.P. | Austin

Mayer Brown JSM advises Sinochem Offshore Capital Company on US$500 million bond offering

Wednesday, April 30, 2014
Mayer Brown JSM today announced that it advised Sinochem Offshore Capital Company Limited in connection with the establishment of its US$1,000,000,000 Medium Term Note Programme, guaranteed by Sinochem Hong Kong (Group) Limited, and its initial takedown of US$500 million 3.25 percent Senior Notes due 2019. The investment grade notes were listed on the Hong Kong Stock Exchange and the proceeds will be used for general corporate purposes.

More >>

Tags:  Mayer Brown LLP

Paul Hastings Advises Joint Bookrunners on Hanwha Chemical Corporation’s US$340 Million GDR Offering

Wednesday, April 30, 2014

Paul Hastings, a leading global law firm, announced today that it represented the joint bookrunners in a US$340 million global depositary receipts (“GDRs”) offering by Hanwha Chemical Corporation, a leading global chemicals company based in Korea that specializes in chemical products and materials for use in the solar power industry. The GDRs will be listed on the Singapore Stock Exchange and the underlying common shares will be listed on the Korea Exchange. More >>

Tags:  Paul Hastings, LLP

Ropes & Gray Represents Sarepta Therapeutics in Follow-On Offering

Wednesday, April 30, 2014
Ropes & Gray represented Sarepta Therapeutics in its public offering of an aggregate of 2,650,000 shares of its common stock at a price of $38 per share. In addition, Sarepta has granted the underwriters a 30-day option to purchase up to 397,500 additional shares of common stock on the same terms and conditions as the initial shares sold to the underwriters. The gross proceeds from the offerings totaled $100.7 million. Bank of America Merrill Lynch, Morgan Stanley and Deutsche Bank Securities are acting as joint book-running managers for the offering, with Baird, William Blair and Canaccord Genuity acting as co-managers. The transaction closed April 29.

More >>

Tags:  Ropes & Gray LLP

Cahill Represents Initial Purchasers in $1.15 Billion Notes Offering by Florida East Coast

Wednesday, April 30, 2014

Cahill represented Morgan Stanley and J.P. Morgan as joint book-running managers and BMO Capital Markets as co-lead manager in connection with the Rule 144A offering of $875,000,000 aggregate principal amount of 6.75% Senior Secured Notes due 2019 and $275,000,000 aggregate principal amount of 9.75% Senior Notes due 2020 by Florida East Coast Holdings Corp. and Florida East Coast Industries, LLC. More >>

Tags:  Cahill Gordon & Reindel LLP

CMS advises Wells Fargo Bank N.A. on its funding of £291 million acquisition

Wednesday, April 30, 2014

CMS is advising Wells Fargo Bank N.A. on its funding of the £291 million acquisition by Cirrus Logic, of Wolfson Microelectronics Plc, which was announced yesterday.

Cirrus, which is listed on NASDAQ, is a premier supplier of high-precision analogue and digital signal processing components for audio and energy markets and is a close partner of Apple. Wolfson is a leading UK audio chip designer that supplies audio components in Samsung’s phones and tablets. More >>

Tags:  CMS

Kirkland & Ellis Advises Furiex Pharmaceuticals in $1.1 Billion Acquisition by Forest Laboratories

Tuesday, April 29, 2014

Kirkland & Ellis LLP advised Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), a drug development collaboration company, in its definitive agreement announced today to be acquired by Forest Laboratories, Inc. (NYSE: FRX) for $95 per share, or approximately $1.1 billion in cash, and up to $30 per share (or approximately $360 million) in Contingent Value Rights (CVR) that may be payable based on the status of eluxadoline, Furiex’s lead product, as a controlled drug following approval.  The acquisition is subject to customary regulatory approvals and approval by Furiex shareholders. More >>

Tags:  Kirkland & Ellis LLP